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Abstract 44 
Background  45 
Overnutrition and undernutrition can affect patients with inflammatory bowel disease (IBD). 46 
Although all IBD outpatients should be screened for nutrition risk, screening is not routinely 47 
performed, potentially leading to reduced identification and treatment. This study aimed to 48 
estimate the prevalence of nutrition risk in adult IBD outpatients and the proportion of 49 
cases who discussed diet and/or nutrition during their routine clinical appointment.  50 
Methods 51 
Adults with IBD attending outpatient clinics at four hospitals in Greece and in UK were 52 
recruited. Demographic and anthropometric data were collected using face-to-face patient 53 
interviews and clinical records. Patients were classified as high (i.e. BMI <18.5kg/m2 or 18.5-54 
20kg/m2 and weight loss >5%), moderate (i.e. BMI 20-25 kg/m2 and weight loss >5%) or low 55 
risk of undernutrition and high risk of obesity (i.e. BMI 25-30% and weight gain >5%). The 56 
proportion of patients who discussed diet and/or nutrition during their clinical appointment 57 
was calculated.   58 
 59 
Results 60 
In total, 390 IBD patients participated. Sixteen (4%) patients were underweight, 113 (29%) 61 
were overweight and 71 (18%) were obese. Twenty-one (5%) patients were at high risk of 62 
undernutrition; of these four (19%) were under dietetic care. Of those at high risk of 63 
undernutrition, 11 (52%) had discussed diet and/or nutrition during their routine clinical 64 
appointment. Fifty-six (14%) patients had gained more than 5% weight since their last 65 
recorded/reported weight and 19 (5%) were at high risk of obesity.  66 
Conclusions 67 
Few patients were identified to be at high risk of undernutrition and less than a fifth of 68 
these were under dietetic care.  Overnutrition is a growing problem in IBD with almost half 69 
of adult patients being overweight or obese. Diet and/or nutrition were not routinely 70 
discussed in this group of IBD outpatients. 71 
  72 
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Introduction 73 
In inflammatory bowel disease (IBD), undernutrition may be caused by reduced oral intake, 74 
increased gastrointestinal losses, raised nutrient requirements and occasionally, drug-75 
nutrient interactions 1.  Patients with active Crohn’s disease (CD) are at greatest risk of 76 
undernutrition, particularly the newly diagnosed 1,2.  77 
Historically, IBD has been associated with undernutrition, however, in recent years, better 78 
disease management and the obesity epidemic may have increased the risk of overnutrition. 79 
Thus, between 15-40% of IBD patients are now reported as overweight or obese 3,4. 80 
Nutrition screening of all inpatients is mandatory and routinely carried out in the health 81 
services of certain countries. Such process identifies patients with or at risk of 82 
undernutrition who will subsequently be referred for comprehensive dietetic assessment 5-7. 83 
There are few reports of nutrition screening in the IBD outpatient setting 8.  84 
Beyond the pharmacological management of active disease, nutrition and diet are 85 
important aspects in the treatment of patients with IBD. However, these are barely 86 
discussed between clinicians and patients in routine IBD practice 9 and despite the fact that 87 
three out of the 10 current priorities for all research in IBD are pertinent to diet 10,11. 88 
The aims of this study were to determine (i) the prevalence of undernutrition and/or 89 
overnutrition in adult IBD outpatient clinics, (ii) the proportion of patients who discussed 90 
with their clinician aspects around diet or nutrition, during their recent appointment and (iii) 91 
the dietetic referral rate for patients identified as at risk of malnutrition by nutrition 92 
screening.  93 
 94 
Methods 95 
All consecutive patients with CD, ulcerative colitis (UC) or IBD unclassified (IBDU) who 96 
attended adult outpatient clinics at four hospitals in Greece and UK (Glasgow Royal 97 
Infirmary, Glasgow, UK; Guy’s and Thomas’ NHS Foundation Trust, London, UK; Ioannina 98 
General Hospital, Ioannina, Greece; Evangelismos-Ophthalmiatreion Athinon-Polykliniki 99 
General Hospital, Athens, Greece) over a period of 8 weeks were eligible to take part. 100 
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Disease diagnosis was ascertained using the European Crohn’s and Colitis Organisation 101 
diagnostic criteria, including endoscopy with biopsies12. As the majority of patients who 102 
attend the clinics above suffer from active symptoms or require treatment at hospital (e.g. 103 
for infusion for biologics) this study was likely to recruit patients with more complicated 104 
disease.  For all centres included in this study, routine screening for disease associated 105 
malnutrition was not compulsory in the outpatient setting. 106 
 107 
Patients were identified by a member of the clinical team and introduced to the researcher. 108 
Selection of patients was based on convenience sampling and in a consecutive, unselected 109 
manner. The researcher verbally introduced the study to the participants and asked if they 110 
would be willing to answer 5 questions and have their weight and height measured. 111 
Information on demographics, disease characteristics, medical and nutritional treatment 112 
were collected from clinical notes and if not available by face-to-face interview with 113 
patients. Current disease activity was reported by patients, following their clinical 114 
appointment, as active or in remission. Previous measurements of weight were recorded 115 
from the clinical notes or were reported by patients. Patients were also asked to report a 116 
decline in usual intake and weight loss over the past week. Likewise, the number of patients 117 
who reported any diet and/or nutrition discussion during their clinician appointment was 118 
recorded (e.g. diet, weight loss or appetite). 119 
Weight (to the nearest 0.1 kg) and height (to the nearest 0.1cm) were measured using 120 
standard operating procedures. Using the World Health Organisation criteria for body mass 121 
index (BMI), underweight was defined as <18.5kg/m2, normal BMI as 18.5-24.9kg/m2, 122 
overweight as 25-29.9kg/m2 and obesity as > 30kg/m2. To define high risk of undernutrition, 123 
we used the first two steps of the Malnutrition Universal Screening Tool (MUST), a tool 124 
widely used in Europe and endorsed for use in the UK, as the third one is more appropriate 125 
for inpatients 13. Therefore, patients with BMI <18.5kg/m2 or 18.5-20kg/m2 and at least 5% 126 
concomitant weight loss between current and previous recorded/reported weight were 127 
classified as high risk of undernutrition as per MUST scoring. This nutrition risk benchmark 128 
we chose is also in accordance to the consensus statement for the diagnostic criteria of 129 
malnutrition endorsed by the European Society for Clinical Nutrition and Metabolism 14. 130 
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Patients with BMI 20-25 kg/m2 and at least 5% weight loss were classified as moderate risk 131 
of undernutrition. Similarly, overweight patients with at least 5% weight gain were classified 132 
as high risk of obesity.   133 
Ethical permission was waived for this study as this was an evaluation of current practice at 134 
each centre15. 135 
 136 
Statistical analysis 137 
Data are presented with descriptive statistics with differences between groups reported 138 
using two sample t-test for continuous data (mean (SD)) and chi-squared test for categorical 139 
data (n (%)). Logistic regression analysis was used to associate risk of malnutrition or obesity 140 
with demographics and disease characteristics. MINITAB 17 and SPSS 24 were used for 141 
statistical analysis. Assuming an estimate of 20% of patients classified at high risk of 142 
undernutrition, with 5% precision and 95% CI, the required sample size is 246 participants. 143 
 144 
Results 145 
In total, 390 patients (CD=247 (63%), UC=127 (33%), IBDU=16 (4%)) were recruited from the 146 
four centres with 175 (55%) reporting active disease (Table 1). Sixteen (4%) patients were 147 
underweight, 190 (49%) were normal weight, 113 (29%) were overweight and 71 (18%) 148 
were obese (Figure 1). Forty-six (12%) patients reported having a reduced intake and 80 149 
(21%) patients self-reported weight loss. Twenty-seven (7%) patients were under the care of 150 
the dietitian.  151 
 152 
Routine evaluation of nutritional and dietary aspects 153 
Aspects around diet and/or nutrition were discussed in 135 (35%) patients during their 154 
clinician appointment. Eighty-nine (23%) patients conveyed a discussion about diet, 91 155 
(23%) about weight loss and 82 (21%) about their appetite during their recent appointment. 156 
Two hundred and fifty-five (65%) patients did not discuss any of these aspects. The extent of 157 
weight loss was significantly higher in patients who had discussed with their clinician aspects 158 
around diet [discussed: -1.15 kg (6.0) versus not discussed: 0.65 (6.2); p=0.016], weight loss 159 
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[discussed: -1.65 kg (6.6) versus not discussed: 0.81 kg (6.0); p=0.002], or appetite 160 
[discussed: -1.62 kg (6.1) versus not discussed: 0.73 kg (6.2); p=0.002]. 161 
 162 
Risk of undernutrition  163 
In total, 21 (5%) patients were at high risk of undernutrition (Figure 1). Of those, only 4 164 
(19%) were under dietetic care and 11 (52%) discussed diet and/or nutrition in their clinician 165 
appointment. Twenty-six (7%) patients were screened at moderate risk of undernutrition. 166 
Of those, only 3 (11%) were under dietetic care and 11 (41%) had a discussion about diet 167 
and/or nutrition in their clinician appointment. 168 
Compared to the patients at low risk of undernutrition, the 47 (12%) patients at moderate 169 
or high risk (combined) were more likely to have a discussion with their clinician about diet 170 
[moderate/high risk: 17 (35%) versus low risk: 72 (21%); p=0.049], weight loss 171 
[moderate/high risk: 22 (46%) versus low risk: 69 (20%); p<0.001], or appetite 172 
[moderate/high risk: 16 (33%) versus low risk: 66 (19%); p=0.050]. The odds ratio for 173 
clinician appointment discussion about weight loss increased (p=0.002) according to their 174 
level of undernutrition risk [OR (95% CI): high risk, 3.6 (1.4 to 8.7); moderate risk 3.1 (1.3 to 175 
7.1)]. Patients at moderate/high risk of undernutrition were younger [moderate/high risk: 176 
36.2 years (13.9) versus low risk: 41.0 years (14.9); p=0.032] and had a shorter disease 177 
duration [moderate/high risk: 7.1 years (9.7) versus low risk: 10.8 years (9.7); p=0.012]. 178 
Patients at moderate/high risk of undernutrition were more likely than those at low risk to 179 
have active disease [moderate/high risk: 34 (71%) versus low risk: 14 (29%); p<0.001]. 180 
Neither BMI (r=0.04, p=0.432) nor recent weight loss (r=-0.02, p=0.728) were associated 181 
with disease duration. There was no difference in the prevalence of high undernutrition risk 182 
between patients with CD and UC (p=0.809).  183 
 184 
Overweight, obesity and risk of obesity      185 
Fifty six (14%) patients had gained more than 5% weight since their last recorded/reported 186 
weight. Apart from the 71 (18%) of the patients who were obese, 19 patients (5%) were at 187 
high risk of obesity. There was no association between obesity or risk of obesity and 188 
discussion during the clinician appointment about diet, weight loss or appetite. There was a 189 
8 
 
weak positive association between BMI and weight gain (r=0.15, p=0.003) and patients who 190 
were either obese or at risk of obesity were older [obese/obesity risk: 43.8 years (14.2) 191 
versus low risk: 39.4 years (14.9); p=0.013]. Disease activity was not associated with obesity 192 
or risk of obesity. Obesity and risk of obesity did not differ by country (p=0.624) or by IBD 193 
subtype (p=0.237).  194 
 195 
There were no major differences for other nutritional outcomes between centres and as the 196 
number of patients at high nutrition risk was small, no statistical analysis by centre was 197 
performed.  198 
Discussion 199 
This study in four hospitals from two European countries identified that only 5 and 7% of 200 
IBD outpatients were at high and moderate risk of undernutrition, respectively. This figure is 201 
lower than the 27-30% of IBD patients reported at high risk of undernutrition in the 202 
literature 8,16. The low prevalence of risk of malnutrition observed in the current study is 203 
likely to be attributed to the enrolment of patients with longstanding disease, in whom 204 
undernutrition is less common than in newly diagnosed and treatment naïve patients, the 205 
better disease management nowadays and may be a reflection of the obesity epidemic in 206 
the general population. In a pooled analysis of 1698 population-based measurement studies 207 
with 19.2 million participants in 200 countries, trends of obesity increased markedly from 208 
1975 to 2014 with approximately 25% of the general Greek and UK population classed as 209 
obese 17. In previous research in CD children, the prevalence of undernutrition dropped 210 
from 35% at diagnosis to 2% at 24-month follow-up and obesity concomitantly increased 18. 211 
It is also unlikely that our findings are explained by having oversampled patients in 212 
remission or with less complicated disease as we enrolled patients attending outpatient 213 
clinics due to ongoing disease symptoms or biologic infusion clinics, as indicated by the 214 
characteristics of our sample (Table 1). 215 
Another important finding of this study is that two-thirds of patients did not discuss diet 216 
and/or nutrition during their clinician appointment which further supports the argument 217 
that this aspect of patient care receives less attention than the management of active 218 
disease 19. Although a small number of patients were at high risk of undernutrition, still in 219 
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almost half of them (43%) diet and/or nutrition were not discussed, thus risk was not 220 
identified nor the appropriate care pathway implemented. 221 
Only 4 (19%) high risk patients were receiving dietetic care, consistent with the findings of 222 
previous research showing that only 15% to 17% of malnourished outpatients receive 223 
nutritional treatment 20,21.  This is of concern given that advice on diet is one of the most 224 
important issues for patients with IBD 10,11,22 and previous authors reported that of those 225 
who had not seen a dietitian, the vast majority would have liked to 23. 226 
It is therefore necessary that appropriate action be taken to help increase the frequency of 227 
nutritional screening in IBD outpatients. One action to overcome barriers with nutritional 228 
screening would be to program the calculation of BMI, percent weight loss and nutritional 229 
risk score into IT systems or allowing patients to input this data remotely supporting self-230 
management; thereby reducing the amount of time the process takes. Patients could be 231 
given the option to screen at home as an alternative to screening during clinical visits 8,24, 232 
which would serve not only to reduce the burden on healthcare staff but also empower 233 
patients to be more involved in their own care 25. However such a process would require 234 
availability of dietetic resources to formally review high risk cases. 235 
A drawback of this study is that BMI has limited use to reflect body composition which 236 
might be a better marker to evaluate the risk of undernutrition and overnutrition in IBD. 237 
This is particularly important as patients with IBD and undernutrition are more likely to 238 
present higher levels of adiposity, for the same unit of BMI as healthy controls, are more 239 
prone to cardiovascular diseases 26,27  and undernutrition can affect adversely their quality 240 
of life and clinical outcomes 28. In this study, percentage weight loss was determined using 241 
the current and last recorded weight. Where the last recorded weight was unavailable, 242 
patients were asked to self-report but this is often normal in routine clinical practice and 243 
incorporated into nutrition screening tools, e.g. MUST 13,29. Likewise, the timeframe within 244 
changes in weight were assessed was not specified and it was therefore variable. However, 245 
both our definition of risk of obesity and undernutrition included patients who were already 246 
overweight or slightly underweight, based on BMI measurements alone. Information on 247 
participants’ co-morbidities and other concomitant gastrointestinal diseases was not 248 
collected but these are unlikely to have influenced the main findings of this study. As this 249 
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was an appraisal of current clinical practice, dietary assessment was not performed and 250 
body composition measurements could not be obtained to describe the eating habits of our 251 
population and the proportion of patients suffering from sarcopenia, obesity or myopenia.  252 
In conclusion, only 4 in every 100 IBD patients were underweight, while almost half were 253 
either overweight or obese. Obesity in IBD has been associated with poor disease outcomes 254 
and patients with IBD are at increased risk of cardiovascular disease 4,27. Therefore, 255 
provision of weight loss interventions as an adjunctive therapy in these individuals is an area 256 
that requires further research. 257 
 258 
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Figure legends 276 
Figure 1: Body mass index and nutrition risk classification    277 
Athens  278 Glasgow Ioannina London 
(a) Body mass index (BMI) is classified as underweight <18.5kg/m2, normal 18.5-24.99kg/m2, 279 
overweight 25-29.99kg/m2, obese >30kg/m2.  280 
(b) High obesity risk was for patients who were at high risk of obesity and had a BMI>25 and 281 
at least 5% concomitant weight gain between current and previous recorded/reported 282 
weight. High risk was for patients at high risk of undernutrition and had a BMI <18.5kg/m2 283 
or 18.5-20kg/m2 and at least 5% concomitant weight loss between current and previous 284 
recorded/reported weight. Moderate risk was for patients at moderate risk of 285 
undernutrition and had a BMI 20-25 kg/m2 and at least 5% concomitant weight loss 286 
between current and previous recorded/reported weight. Low risk was for patients at low 287 
risk of undernutrition or obesity not in any of the above categories. 288 
289 
  290 
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 Table 1: Participants characteristics 
 Athens Glasgow Ioannina London  Total  
 100 65 90 135 390 
Mean (SD)      
Age, y 39.1 (13.1) 44.1 (17.6) 43.6 (15.7) 37.5 (13.2) 10.5 (9.5) 
Weight, kg 73.5 (15.2) 74.1 (15.2) 74.3 (16.6) 74.4 (16.6) 74.1 (16.0) 
Height, cm 170 (9.9) 169 (10) 171 (10) 170 (10) 170 (10) 
BMI, kg/m2 25.3 (4.6) 26.2 (5.2) 25.3 (4.5) 25.6 (5.0) 25.6 (4.8) 
Disease duration, y 10.7 (8.2) 11.1 (10.1) 9.0 (11.3) 10.9 (11.3) 10.5 (9.5) 
N (%)      
Gender      
Males 50 (50) 28 (43) 53 (59) 72 (53) 203 (52) 
Females 50 (50) 37 (57) 37 (41) 63 (47) 187 (48) 
Disease*      
UC 32 (32) 13 (20) 32 (32) 44 (32) 127 (33) 
CD 66 (67) 47 (72) 66 (67) 82 (61) 247 (63) 
IBDU 1 (1) 5 (8) 1 (1) 9 (7) 16 (4) 
Disease activity*      
Remission 64 (64) 32 (49) 58 (64) 61 (45) 215 (55) 
Active 36 (36) 33 (51) 32 (36) 74 (55) 175 (45) 
Medication      
Azathioprine* 24 (24) 33 (51) 41 (30) 41 (30) 139 (36) 
5-ASAs* 52 (52) 31 (48) 2 (2) 44 (33) 129 (33) 
Biologics* 30 (30) 20 (31) 57 (63) 42 (31) 149 (38) 
Oral steroids 12 (12) 9 (14) 6 (7) 17 (13) 44 (11) 
Vitamins/minerals* 24 (24) 15 (23) 5 (6) 71 (53) 115 (29) 
Nutritional supplements 3 (3) 2 (3) 0 (0) 7 (5) 12 (3) 
* p<0.05 between centres 
 
 
